Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

[1]  D. Stocken,et al.  Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. , 2017 .

[2]  E. Assenat,et al.  Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. , 2017 .

[3]  M. Manns,et al.  The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis , 2017, Journal of Cancer Research and Clinical Oncology.

[4]  M. Nagino,et al.  Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis , 2017, Surgery Today.

[5]  R. Oster,et al.  Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[6]  Andrew X. Zhu,et al.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise , 2016, The oncologist.

[7]  Young Saing Kim,et al.  The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas , 2016, Cancer Chemotherapy and Pharmacology.

[8]  T. Goetze.  Gallbladder carcinoma: Prognostic factors and therapeutic options. , 2015, World journal of gastroenterology.

[9]  F. Miura,et al.  Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer , 2015, Journal of hepato-biliary-pancreatic sciences.

[10]  L. Dawson,et al.  Outcome of Adjuvant Therapy in Biliary Tract Cancers , 2015, American journal of clinical oncology.

[11]  David Goldstein,et al.  Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial , 2015 .

[12]  Kyubo Kim,et al.  Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. , 2015, Annals of surgery.

[13]  P. Parikh,et al.  A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[14]  T. Pawlik,et al.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.

[15]  A. Miyamoto,et al.  Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004) , 2014, Cancer Chemotherapy and Pharmacology.

[16]  A. Miyamoto,et al.  Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). , 2014 .

[17]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[18]  H. Cortés-Funes,et al.  Chemotherapy for cholangiocarcinoma: An update. , 2013, World journal of gastrointestinal oncology.

[19]  M. Büchler,et al.  Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.

[20]  J. Knox,et al.  Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Bridgewater,et al.  BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[23]  T. Brunner,et al.  Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Y. Murakami,et al.  Gemcitabine-Based Adjuvant Chemotherapy Improves Survival After Aggressive Surgery for Hilar Cholangiocarcinoma , 2009, Journal of Gastrointestinal Surgery.

[25]  E. Hatano,et al.  Single-Agent Gemcitabine for Biliary Tract Cancers , 2007, Oncology.

[26]  E. Hatano,et al.  Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. , 2006, Oncology.

[27]  H. Thomas,et al.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours. , 2002, Journal of hepatology.

[28]  H. Thomas,et al.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document , 2002, Gut.

[29]  M. Manns,et al.  Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. , 2001, Hepato-gastroenterology.

[30]  F. Verderame,et al.  Biliary tract cancer: our experience with gemcitabine treatment. , 2000, Anti-cancer drugs.

[31]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Takada,et al.  Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. , 1994, Oncology.